Sanofi-Aventis Announces Approval of Labelling Update of Acomplia® in Europe
Acomplia® labelling has been updated based on data reflecting one year of post-marketing experience mainly from Germany, France and the UK, as well as results of five additional clinical trials completed since the original dossier was approved.
With this updated labelling, Acomplia® is now contraindicated in patients with ongoing major depressive illness and/or ongoing anti-depressive treatment. “Special Warnings and Precautions” of the Summary of Product Characteristics (SmPC) have been updated as well to include information on depressive disorders.
The SpiroScout SP incorporates the latest ultrasound technology and can be used in combination with SCHILLER ECG devices. This new concept offers many benefits, as it simplifies the handling of the measurements and the data management for both ECG and...